To our knowledge, this is the first clinical trial to prospectively report that the combination of low-dose nab-paclitaxel and tislelizumab is well tolerated and leads to promising outcomes in elderly patients with advanced NSCLC, including patients with EGFR or ALK variations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.